New drug candidate targets Hard-to-Treat blood cancers

NCT ID NCT01594723

Ongoing Disease control Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an experimental drug called LY2784544 in people with three types of blood cancers known as myeloproliferative neoplasms: polycythemia vera, essential thrombocythemia, and myelofibrosis. The trial enrolls patients who have not responded to, cannot tolerate, or have stopped responding to standard treatments, including ruxolitinib. The main goal is to see how many patients respond to the drug, with additional measures including molecular changes, spleen size, and symptom improvement.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: LY2784544
What this could lead to: If successful, this could offer a new treatment option for people with certain blood cancers who have not responded to current therapies.
What could go wrong: This is an early-phase trial with a small number of participants, so results may not apply to everyone. The drug may cause side effects or fail to show benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acquired polycythemia vera essential thrombocythemia hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm myelofibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEOPLASMS, HEMATOLOGIC

Contacts and locations

Locations

Albert Einstein College of Medicine

The Bronx, New York, 10461, United States
Baptist Cancer Center

Memphis, Tennessee, 38120, United States
Cancer Center of Kansas

Wichita, Kansas, 67214, United States
Cleveland Clinic Foundation

Cleveland, Ohio, 44195, United States
Dana Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Dean Medical Center

Madison, Wisconsin, 53717, United States
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Garran, Australian Capital Territory, 2605, Australia
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Wodonga, Victoria, 3690, Australia
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Perth, Western Australia, 6009, Australia
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Vienna, 1090, Austria
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Montreal, Quebec, H1T 2M4, Canada
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Paris, 75010, France
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Jena, 07747, Germany
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Mannheim, 68167, Germany
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Minden, 32429, Germany
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Bologna, 40138, Italy
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Florence, 50134, Italy
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Barcelona, 08036, Spain
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Madrid, 28046, Spain
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Stockholm, SE-118 83, Sweden
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Uddevalla, 45180, Sweden
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Uppsala, 75185, Sweden
Greenebaum Comprehensive Cancer Center

Baltimore, Maryland, 21201, United States
Highlands Oncology Group - Duplicate 2

Rogers, Arkansas, 72758, United States
Indiana Blood & Marrow Transplantation (IBMT)

Indianapolis, Indiana, 46237, United States
Ingalls Memorial Hospital

Harvey, Illinois, 60426, United States
Joe Arrington Cancer Center

Lubbock, Texas, 79410, United States
Lakeland Regional Cancer Center

Lakeland, Florida, 33805, United States
Medical College of Wisconsin

Milwaukee, Wisconsin, 53226, United States
Mid Ohio Oncology Hematology

Columbus, Ohio, 43219, United States
Nebraska Methodist Hospital

Omaha, Nebraska, 68114, United States
Norwalk Hospital

Norwalk, Connecticut, 06856, United States
Palm Beach Cancer Institue

West Palm Beach, Florida, 33401, United States
Providence St. Joseph's Medical Center

Burbank, California, 91505, United States
Sarah Cannon Cancer Center

Nashville, Tennessee, 37203, United States
Swedish Medical Center

Seattle, Washington, 98104, United States
Tennessee Oncology PLLC

Nashville, Tennessee, 37203, United States
Washington University Medical Center

St Louis, Missouri, 63110, United States
Weill Cornell Medical College

New York, New York, 10021, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.